A Health Canada news release says it's due to potential contamination with the antibiotic product clindamycin during the manufacturing process.
Health Canada says quetiapine is used in the treatment of schizophrenia and bipolar disorder in adult patients.
Health Canada says it has not received any reports of adverse reactions from the product.
The government says those at risk includes people who are susceptible or hypersensitive to the antibiotics clindamycin or lincomycin, but estimates the number of patients in question is small.
Health Canada says the possibility of contamination was spotted at the pharmaceutical factory in China that produces quetiapine for the three companies _ Cobalt Pharmaceuticals Company, Laboratoires Riva Inc. and Sanis Health Inc.
Health Canada says the products affected include all lots of 25 mg, 100 mg, 200 mg and 300 mg doses of Co Quetiapine (Cobalt Pharmaceuticals Company), Riva Quetiapine (Laboratoires Riva Inc.), and Sanis Quetiapine (Sanis Health Inc.)
Health Canada said in an email that the recall represents less than 25 per cent of the quetiapine marketed in Canada.Suggest a correction